These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10803041)

  • 1. [Pharma-clinics. Medication of the month. Moxonidine (Moxon)].
    Scheen AJ
    Rev Med Liege; 2000 Jan; 55(1):61-3. PubMed ID: 10803041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxonidine: a review of its use in essential hypertension.
    Fenton C; Keating GM; Lyseng-Williamson KA
    Drugs; 2006; 66(4):477-96. PubMed ID: 16597164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
    Ernsberger P; Damon TH; Graff LM; Schäfer SG; Christen MO
    J Pharmacol Exp Ther; 1993 Jan; 264(1):172-82. PubMed ID: 8380858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxonidine: a new and versatile antihypertensive.
    Messerli F
    J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S53-6. PubMed ID: 11346219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxonidine for hypertension.
    Drug Ther Bull; 1997 May; 35(5):33-6. PubMed ID: 9282418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxonidine: pharmacology, clinical pharmacology and clinical profile.
    Elliott HL
    Blood Press Suppl; 1998; 3():23-7. PubMed ID: 10321451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
    Armah BI; Hofferber E; Stenzel W
    Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renaissance of centrally acting antihypertensive drugs.
    van Zwieten PA
    J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension.
    Chrisp P; Faulds D
    Drugs; 1992 Dec; 44(6):993-1012. PubMed ID: 1282869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective stimulation of I1-imidazoline receptors as a novel mechanism for antihypertensive action. Focus on moxonidine.
    Papp JG; Ollivier JP
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():v-vi. PubMed ID: 7533220
    [No Abstract]   [Full Text] [Related]  

  • 15. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
    van Zwieten PA
    Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commissural nucleus of the solitary tract regulates the antihypertensive effects elicited by moxonidine.
    Totola LT; Alves TB; Takakura AC; Ferreira-Neto HC; Antunes VR; Menani JV; Colombari E; Moreira TS
    Neuroscience; 2013 Oct; 250():80-91. PubMed ID: 23850502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension].
    Zaslavskaia RM; Komarov FI; Shakirova AN; Teĭblium MM; Akhmetov KZh
    Klin Med (Mosk); 2000; 78(4):41-4. PubMed ID: 10833890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New, modern, centrally active antihypertensive agents in the treatment of essential hypertension].
    Sevcík J; Masek K
    Cas Lek Cesk; 1999 Jun; 138(12):359-62. PubMed ID: 10566202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxonidine: a review of safety and tolerability after seven years of clinical experience.
    Schachter M
    J Hypertens Suppl; 1999 Aug; 17(3):S37-9. PubMed ID: 10489097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of moxonidine in the treatment of hypertension.
    Prichard BN; Graham BR
    J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.